| CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2026 |
| Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.Obesity (Silver Spring) | Pooled analysis | 2026 |
| Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.Ann Intern Med | Pooled analysis | 2026 |
| Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.BMJ | Pooled analysis | 2026 |
| Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.Endocrinol Diabetes Metab | Pooled analysis | 2026 |
| Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.Diabetes Obes Metab | Pooled analysis | 2026 |
| CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.Am J Cardiol | Pooled analysis | 2026 |
| Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.Endocrinol Diabetes Metab | Pooled analysis | 2026 |
| Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis.Biomed Pharmacother | Pooled analysis | 2024 |
| Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.BMJ | Pooled analysis | 2024 |
| Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.Diabetes Obes Metab | Random groups | 2026 |
| Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.Lancet Gastroenterol Hepatol | Random groups | 2026 |
| Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.Lancet Diabetes Endocrinol | Random groups | 2026 |
| Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.Lancet Diabetes Endocrinol | Random groups | 2026 |
| Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.Lancet | Random groups | 2026 |
| Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clin Pharmacokinet | Random groups | 2026 |
| Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.Lancet Diabetes Endocrinol | Random groups | 2026 |
| CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.Hypertension | Random groups | 2026 |
| Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.Mol Metab | Random groups | 2025 |
| Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.N Engl J Med | Random groups | 2025 |
| Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes Obes Metab | Random groups | 2024 |
| Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet | Random groups | 2023 |
| Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet | Random groups | 2021 |
| Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?Lancet | Review of studies | 2026 |
| Medical treatments for obesity: what does the future have in store?J Clin Endocrinol Metab | Review of studies | 2026 |
| Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.Nutr Clin Pract | Review of studies | 2026 |
| Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.Ann Intern Med | Review of studies | 2026 |
| Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.Pharmacol Res | Review of studies | 2026 |
| New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.Diabetes Ther | Review of studies | 2026 |
| Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists.Cureus | Review of studies | 2026 |
| Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.World J Clin Pediatr | Review of studies | 2026 |
| Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.Diabetes Metab Syndr Obes | Review of studies | 2026 |
| Pharmacological management of obesity: Current landscape and emerging therapies.Indian J Pharmacol | Review of studies | 2026 |
| Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.Diabetes Obes Metab | Review of studies | 2026 |
| Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.Naunyn Schmiedebergs Arch Pharmacol | Review of studies | 2026 |
| Beyond weight loss: multisystem benefits of obesity medications.Lancet Diabetes Endocrinol | Review of studies | 2026 |
| Incretin analogues as cardiovascular agents: a state-of-the-art review.Front Endocrinol (Lausanne) | Review of studies | 2026 |
| Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.J Diabetes Metab Disord | Review of studies | 2026 |
| Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.Metabol Open | Review of studies | 2026 |
| Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050.Clin Nutr ESPEN | Review of studies | 2026 |
| Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists.Pharmaceutics | Review of studies | 2026 |
| Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders.Clin Mol Hepatol | Review of studies | 2026 |
| New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.Nutrients | Review of studies | 2026 |
| Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.Endocr Rev | Review of studies | 2026 |
| Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.Peptides | Review of studies | 2026 |
| Bariatric Surgery in the Era of GLP1RA: A Narrative Review.Adv Ther | Review of studies | 2026 |
| Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.Vascul Pharmacol | Review of studies | 2026 |
| Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.J Obes Metab Syndr | Review of studies | 2026 |
| Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.J Obes | Review of studies | 2025 |
| Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.J Clin Med | Review of studies | 2025 |
| Weight management treatment in obesity.Med Clin (Barc) | Review of studies | 2025 |
| Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.World J Cardiol | Review of studies | 2025 |
| Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.Diabetes Ther | Review of studies | 2025 |
| Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.Peptides | Review of studies | 2025 |
| Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review.Diseases | Review of studies | 2025 |
| Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review.Cureus | Review of studies | 2025 |
| The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.Expert Opin Investig Drugs | Review of studies | 2025 |
| What is the pipeline for future medications for obesity?Int J Obes (Lond) | Review of studies | 2025 |
| Central nervous system pathways targeted by amylin in the regulation of food intake.Biochimie | Review of studies | 2025 |
| Emerging pharmacotherapies for obesity: A systematic review.Pharmacol Rev | Review of studies | 2025 |
| Incretin-based therapies for the treatment of obesity-related diseases.NPJ Metab Health Dis | Review of studies | 2024 |
| Amylin analogs for the treatment of obesity without diabetes: present and future.Expert Rev Clin Pharmacol | Review of studies | 2024 |
| Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.Indian J Endocrinol Metab | Review of studies | 2024 |
| Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.Indian J Endocrinol Metab | Review of studies | 2024 |
| Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?Expert Opin Pharmacother | Review of studies | 2024 |
| Advancements in the management of obesity: a review of current evidence and emerging therapies.Expert Rev Endocrinol Metab | Review of studies | 2024 |
| Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?Expert Opin Pharmacother | Review of studies | 2024 |
| Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity.Int J Mol Sci | Review of studies | 2024 |
| Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity.Curr Diabetes Rev | Review of studies | 2024 |
| Polyagonists in Type 2 Diabetes Management.Curr Diab Rep | Review of studies | 2024 |
| Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness - a narrative review.Expert Opin Pharmacother | Review of studies | 2023 |
| Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon.J Obes Metab Syndr | Review of studies | 2023 |
| An update on peptide-based therapies for type 2 diabetes and obesity.Peptides | Review of studies | 2023 |
| Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?touchREV Endocrinol | Review of studies | 2022 |
| Creating the amylin story.Appetite | Review of studies | 2022 |
| Long-acting amylin analogues for the management of obesity.Curr Opin Endocrinol Diabetes Obes | Review of studies | 2022 |
| Amyloidogenicity of peptides targeting diabetes and obesity.Colloids Surf B Biointerfaces | Review of studies | 2022 |
| Amylin as a Future Obesity Treatment.J Obes Metab Syndr | Review of studies | 2021 |
| Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity.Expert Opin Emerg Drugs | Review of studies | 2021 |
| Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.Physiol Behav | In animals | 2026 |
| Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.Nat Metab | In animals | 2026 |
| Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.Nat Metab | In animals | 2026 |
| Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.EBioMedicine | In animals | 2025 |
| CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure.Nat Metab | In animals | 2025 |
| Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.Biomed Pharmacother | In animals | 2022 |
| Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.Mol Metab | Other paper | 2026 |
| Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.Diabetes Obes Metab | Other paper | 2026 |
| Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3).Am Heart J | Other paper | 2026 |
| Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.Diabetes Metab Syndr Obes | Other paper | 2026 |
| Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.BMJ Med | Other paper | 2026 |
| Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Ann Med Surg (Lond) | Other paper | 2026 |
| Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.Lancet Diabetes Endocrinol | Other paper | 2026 |
| Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes.J Diabetes Sci Technol | Other paper | 2026 |
| In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research.J Pharm Biomed Anal | Other paper | 2026 |
| A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.Nat Metab | Other paper | 2026 |
| Cellular loci for cagrilintide action identified.Nat Metab | Other paper | 2026 |
| Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.J Cachexia Sarcopenia Muscle | Other paper | 2026 |
| Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.Acta Pharmacol Sin | Other paper | 2026 |
| Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis.BMJ Open | Other paper | 2025 |
| Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes.Metabol Open | Other paper | 2025 |
| Development of a potent Xenopus GLP-1-derived GLP-1/GIP/Y2 receptor tri-agonist for obesity and type 2 diabetes.Int J Biol Macromol | Other paper | 2025 |
| In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.Ann Intern Med | Other paper | 2025 |
| Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.Life Sci | Other paper | 2025 |
| Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials.BMJ Open | Other paper | 2025 |
| Advancing Diabetes Management and Glycemic Control While Exploring CagriSema's Impact on Obesity Management.Cardiol Rev | Other paper | 2025 |
| Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.Nat Commun | Other paper | 2025 |
| A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide's Effects on Energy Balance.bioRxiv | Other paper | 2025 |
| Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy.Peptides | Other paper | 2024 |
| Recent advances in peptide-based therapies for obesity and type 2 diabetes.Peptides | Other paper | 2024 |
| Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.Cardiol Rev | Other paper | 2024 |
| Drugs for Treating Obesity.Handb Exp Pharmacol | Other paper | 2022 |
| Development of Cagrilintide, a Long-Acting Amylin Analogue.J Med Chem | Other paper | 2021 |
| AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.J Pharmacol Exp Ther | Other paper | 2021 |